Nerviano Medical Sciences received Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia
NERVIANO, IT and BOSTON, Mass, 9 January, 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced that the […]
Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery
NERVIANO Italy and PARIS France, January 8, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, and Nerviano Medical Sciences S.r.l (NMS), a leading Italian clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, today announced a collaboration agreement in AI for unprecedented kinase project. As per […]
Nerviano Medical Sciences S.r.l.’s Landmark Article in The Journal of Organic Chemistry
Nerviano Medical Sciences Srl (NMS) is pleased to announce the publication of the hot-off-the-press article “Photocatalytic Radical Coupling of Organoborates with α-Halogenated Electron-Poor Olefins” published in The Journal of Organic Chemistry (https://doi.org/10.1021/acs.joc.3c02386) . The paper reports the unprecedented light-mediated construction of elaborated α-halo-derivatives, useful intermediates in organic synthesis. This brilliant achievement was accomplished by […]
Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate
NERVIANO and MILAN, Italy, December 14, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC). Under the terms of the agreement, ITF will use NMS’s […]
Serena Alvino Appointed as Chief Legal, Biotech & Transaction NMS S.r.l., Bringing Extensive Global Biopharmaceutical Experience
NERVIANO, IT and BOSTON, Mass, December 1, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment […]
Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
Valsasina B, Orsini P, Caruso M, Albanese C, Ciavolella A, Cucchi U, Fraietta I, Melillo N, Fiorentini F, Rizzi S, Salsa M, Isacchi A, Gasparri F Mol Cancer Ther (2023), 22(12), 1465-1478
NMS S.r.l. proudly takes part of the Mentoring Program 2024 organized by the Italian Chemical Society
We are pleased to announce that Dr. Gianluca Papeo and Dr. Maurizio Pulici from NMS Srl are invited to be part of the permanent round table of the Pharmaceutical Division of the Italian Chemical Society (SCI) which gathers representative of the Italian Pharmaceutical industry and the Academic world to liaise their relationships under the patronage […]
Tiziano Lazzaretti Appointed as CFO to Drive Financial Strategy at NMS S.r.l.
NERVIANO, IT and BOSTON, Mass, November 2, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment […]
Nerviano Medical Sciences S.r.l. to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC 2023: Poster
Nerviano Medical Sciences Presents Preliminary, Encouraging Clinical Phase 1 Data for PARP-1 Selective Inhibitor at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics NERVIANO, IT and BOSTON, Mass, October 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned […]
Nerviano Medical Sciences S.r.l. : We are attending the 2023 BIO Europe partnering event in Munich, Germany.
We are attending the 2023 BIO Europe partnering event in Munich, Germany. NMS Group- Nerviano Medical Sciences will participate to the 2023 BIO Europe partnering event, which will be held in Munich from November 6th to 8th, 2023 and online from November 14th to 15th, 2023. We are looking forward to your […]
